New collaboration will enable bioprinting of patient-specific cancer tumors

Written by Freya Leask

CELLINK will partner with CTIBIOTECH to develop new predictive human cell models to accelerate drug development CTIBIOTECH (France) has signed a new collaboration agreement to utilize CELLINK (Sweden) bioprinting technology to develop new patient-specific models for cancer drug development. There is currently a high attrition rate in cancer drug development of over 40%, and it is hoped that more effective in vitro models capable of accurately predicting candidate effectiveness and patient-drug interactions will accelerate the drug development process. Using the BIO X 3D printing system and bioinks, CTIBIOTECH aims to develop complex multi-cellular systems to produce patient-specific tumor models. Cheaper...

To view this content, please register now for access

It's completely free